



**DHRHealth**



**DHRHealth**  
Institute for Research  
and Development

To Discover | To Innovate | To Excel

## **Q&A:      **FOURTH** DOSE OF PFIZER COVID-19 mRNA VACCINE**

**Q:      Why get the fourth dose of Pfizer COVID-19 mRNA vaccine?**

**A:      Recent evidence from clinical studies have shown that the best protection against the current pandemic due to Omicron variant is afforded by getting a fourth dose of Pfizer COVID-19 mRNA vaccine 90 days after the third dose of the vaccine**

**Q:      Is this treatment approved by the FDA?**

**A:      Yes, FDA has reviewed the protocol and after much deliberations extended an Expanded Access Authorization. DHR Health Institute for Research & Development is the first and only entity in the US which has received formal approval from the FDA to administer the fourth dose.**

**Q:      Which vaccine will be used for this protocol:**

**A:      Pfizer (Comirnaty; Pfizer/BioNTech) COVID-19 mRNA vaccine will be used for the fourth dose**

**Q:      Who would qualify for fourth dose of the Pfizer COVID-19 mRNA vaccine?**

**A:      The following individuals would qualify for the fourth dose:**

- **≥18 years of age**
- **Healthcare worker, and/or**
- **≥65 years of age, and/or**
- **Immunocompromised**
- **≥90 days after the third dose of Pfizer COVID-19 vaccine**

**Q:      Where will the treatment be administered?**

**A:      Under controlled condition, the fourth dose will be administered in a “safe” zone in the DHR Health Institute for Research & Development**

**Q:      Is there any cost to the subjects?**

**A:      COVID-19 vaccine is available free-of-cost. However, there is standard cost for administering the vaccine and post-vaccine monitoring. This is billed to insurance or third party and/or to the patient**

**Treatment Site:**  
**DHR HEALTH INSTITUTE FOR RESEARCH & DEVELOPMENT**  
**[5323 S. MCCOLL ROAD, EDINBURG](#)**

**For more information or to refer your patient please call: 956-362-2392 or 956-362-2387; or send an email to [dhrrresearch@dhr-rgv.com](mailto:dhrrresearch@dhr-rgv.com); or fax relevant patient information to 956-362-2383**